MX351353B - Composiciones farmacéuticas basadas en shk y métodos para prepararlas y usarlas. - Google Patents
Composiciones farmacéuticas basadas en shk y métodos para prepararlas y usarlas.Info
- Publication number
- MX351353B MX351353B MX2013014401A MX2013014401A MX351353B MX 351353 B MX351353 B MX 351353B MX 2013014401 A MX2013014401 A MX 2013014401A MX 2013014401 A MX2013014401 A MX 2013014401A MX 351353 B MX351353 B MX 351353B
- Authority
- MX
- Mexico
- Prior art keywords
- cys
- thr
- lys
- ser
- arg
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/12—Gas jars or cylinders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
Abstract
La presente invención se refiere a las composiciones farmacéuticas que tienen la secuencia Arg-Ser-Cys-lle-Asp-ThrIle-P ro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Ar g-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEC ID NO: 1). Las composiciones descritas pueden incluir un ácido o una amida en el C-terminal de la SEC ID NO: 1 y el polipéptido puede unirse a una entidad química orgánica o inorgánica que tiene una carga aniónica. El polipéptido puede etiquetarse de manera detectable para las finalidades de diagnóstico. También se describen los métodos de fabricación y de uso de los compuestos farmacéuticos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161493868P | 2011-06-06 | 2011-06-06 | |
US201261625578P | 2012-04-17 | 2012-04-17 | |
PCT/US2012/040857 WO2012170392A2 (en) | 2011-06-06 | 2012-06-05 | Shk-based pharmaceutical compositions and methods of manufacturing and using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013014401A MX2013014401A (es) | 2014-09-25 |
MX351353B true MX351353B (es) | 2017-10-11 |
Family
ID=47296695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013014401A MX351353B (es) | 2011-06-06 | 2012-06-05 | Composiciones farmacéuticas basadas en shk y métodos para prepararlas y usarlas. |
Country Status (13)
Country | Link |
---|---|
US (3) | US9381261B2 (es) |
EP (2) | EP3263123A3 (es) |
JP (2) | JP6250536B2 (es) |
KR (1) | KR20140038501A (es) |
CN (1) | CN103687608B (es) |
AU (2) | AU2012268441B2 (es) |
BR (1) | BR112013031370A2 (es) |
CA (1) | CA2838474A1 (es) |
MX (1) | MX351353B (es) |
RU (1) | RU2637085C2 (es) |
SG (2) | SG195302A1 (es) |
TW (2) | TW201542231A (es) |
WO (1) | WO2012170392A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6250536B2 (ja) | 2011-06-06 | 2017-12-20 | ケイ・ブイ・1.3・セラピューティクス・インコーポレイテッド | Shkベースの薬学的組成物とその製造方法および使用方法 |
CA2916725A1 (en) * | 2013-07-22 | 2015-01-29 | Kineta One, Llc | Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof |
US10246496B2 (en) * | 2014-08-15 | 2019-04-02 | La Trobe University | Potassium channel blockers and use thereof in the treatment of autoimmune diseases |
RS62866B1 (sr) | 2015-05-01 | 2022-02-28 | Onl Therapeutics Inc | Kompozicije peptida i postupci upotrebe |
KR102533290B1 (ko) * | 2022-04-14 | 2023-05-16 | 한국해양과학기술원 | 전압개폐 칼륨이온채널 억제 활성능을 갖는 펩타이드 |
KR102553070B1 (ko) * | 2022-06-16 | 2023-07-07 | 한국해양과학기술원 | 전압개폐 칼륨이온채널 억제 활성능을 갖는 작은상자해파리 기원 펩타이드 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
US5084350A (en) | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
DK0585368T3 (da) | 1991-04-25 | 1998-03-16 | Univ Brown Res Found | Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter |
DK0802800T3 (da) | 1993-08-12 | 2002-10-07 | Neurotech Sa | Biokompatible immunoisolatoriske kapsler indeholdende genetisk ændrede celler for levering af biologisk aktive molekyler |
AU7093396A (en) * | 1995-09-07 | 1997-03-27 | Elan Medical Technologies Limited | Medicament conversion system |
US6077680A (en) * | 1996-11-27 | 2000-06-20 | The University Of Florida | ShK toxin compositions and methods of use |
WO1999013895A1 (en) * | 1997-09-17 | 1999-03-25 | University Of Florida | Polypeptide compositions that inhibit potassium channel activity and uses therefor |
EP0953576B1 (en) * | 1998-04-30 | 2005-11-02 | Curis, Inc. | Active hedgehog protein conjugate, process for its production and use |
EP2474316B1 (en) | 2004-10-07 | 2016-04-06 | The Regents of The University of California | Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels |
US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
CN101282756A (zh) | 2005-06-21 | 2008-10-08 | 伊莱利利公司 | 注射药物的装置和方法 |
US20110163469A1 (en) | 2005-12-16 | 2011-07-07 | Massachusetts Institute Of Technology | High-throughput fabrication of microparticles |
WO2009021289A1 (en) * | 2007-08-14 | 2009-02-19 | The Walter And Eliza Hall Institute Of Medical Research | Potassium channel inhibitors |
US8722079B2 (en) | 2008-04-18 | 2014-05-13 | Warsaw Orthopedic, Inc. | Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine |
MX347291B (es) * | 2009-03-20 | 2017-04-17 | Amgen Inc | Inmunoglobulinas portadoras y usos de las mismas. |
JP6250536B2 (ja) | 2011-06-06 | 2017-12-20 | ケイ・ブイ・1.3・セラピューティクス・インコーポレイテッド | Shkベースの薬学的組成物とその製造方法および使用方法 |
SG11201401193XA (en) * | 2011-10-03 | 2014-05-29 | Univ California | TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS |
CN105873570A (zh) * | 2013-12-23 | 2016-08-17 | 奇尼塔有限责任公司 | 治疗性蛋白质的持续释放储槽式调配物和其用途 |
-
2012
- 2012-06-05 JP JP2014514545A patent/JP6250536B2/ja not_active Expired - Fee Related
- 2012-06-05 RU RU2013157823A patent/RU2637085C2/ru not_active IP Right Cessation
- 2012-06-05 EP EP17175832.9A patent/EP3263123A3/en not_active Withdrawn
- 2012-06-05 TW TW104110742A patent/TW201542231A/zh unknown
- 2012-06-05 CA CA2838474A patent/CA2838474A1/en not_active Abandoned
- 2012-06-05 AU AU2012268441A patent/AU2012268441B2/en not_active Ceased
- 2012-06-05 EP EP12797181.0A patent/EP2717899A4/en not_active Withdrawn
- 2012-06-05 WO PCT/US2012/040857 patent/WO2012170392A2/en active Application Filing
- 2012-06-05 TW TW101120237A patent/TWI535455B/zh not_active IP Right Cessation
- 2012-06-05 SG SG2013089842A patent/SG195302A1/en unknown
- 2012-06-05 SG SG10201604468QA patent/SG10201604468QA/en unknown
- 2012-06-05 CN CN201280035051.7A patent/CN103687608B/zh not_active Expired - Fee Related
- 2012-06-05 MX MX2013014401A patent/MX351353B/es active IP Right Grant
- 2012-06-05 BR BR112013031370A patent/BR112013031370A2/pt not_active IP Right Cessation
- 2012-06-05 US US14/124,669 patent/US9381261B2/en active Active - Reinstated
- 2012-06-05 KR KR1020147000102A patent/KR20140038501A/ko not_active Application Discontinuation
-
2015
- 2015-08-26 US US14/836,700 patent/US9878058B2/en active Active
-
2016
- 2016-07-01 US US15/201,209 patent/US20160331847A1/en not_active Abandoned
- 2016-07-29 AU AU2016208422A patent/AU2016208422A1/en not_active Abandoned
-
2017
- 2017-07-07 JP JP2017133701A patent/JP2018008955A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
BR112013031370A2 (pt) | 2016-11-29 |
TW201542231A (zh) | 2015-11-16 |
CA2838474A1 (en) | 2012-12-13 |
CN103687608A (zh) | 2014-03-26 |
MX2013014401A (es) | 2014-09-25 |
KR20140038501A (ko) | 2014-03-28 |
US20160331847A1 (en) | 2016-11-17 |
US20140221271A1 (en) | 2014-08-07 |
EP3263123A3 (en) | 2018-05-16 |
AU2012268441A1 (en) | 2013-12-19 |
SG195302A1 (en) | 2013-12-30 |
EP3263123A2 (en) | 2018-01-03 |
SG10201604468QA (en) | 2016-07-28 |
TW201300133A (zh) | 2013-01-01 |
JP2018008955A (ja) | 2018-01-18 |
AU2012268441B2 (en) | 2016-05-12 |
EP2717899A4 (en) | 2015-07-29 |
WO2012170392A3 (en) | 2013-03-14 |
US9878058B2 (en) | 2018-01-30 |
RU2013157823A (ru) | 2015-07-20 |
TWI535455B (zh) | 2016-06-01 |
CN103687608B (zh) | 2018-06-26 |
JP6250536B2 (ja) | 2017-12-20 |
WO2012170392A2 (en) | 2012-12-13 |
AU2016208422A1 (en) | 2016-08-18 |
RU2637085C2 (ru) | 2017-11-29 |
US9381261B2 (en) | 2016-07-05 |
JP2014517005A (ja) | 2014-07-17 |
EP2717899A2 (en) | 2014-04-16 |
US20160045627A1 (en) | 2016-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014000466A2 (pt) | polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos | |
SG195302A1 (en) | Shk-based pharmaceutical compositions and methods of manufacturing and using the same | |
IN2014CN02527A (es) | ||
NZ601374A (en) | Stabilized antibody-containing liquid formulations | |
NZ630536A (en) | Therapeutic agent or prophylactic agent for dementia | |
WO2011106322A3 (en) | Biomarkers for acute ischemic stroke | |
WO2013152351A3 (en) | Fusion polypeptides and methods of use thereof | |
BR112013000650A2 (pt) | poliptídeos de fator ix e métodos de uso dos mesmos. | |
MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
IN2014DN03424A (es) | ||
MX346500B (es) | Metodos y composiciones para inmunoterapia para enfermedad neural. | |
IN2014DN09922A (es) | ||
EP2686688A4 (en) | SYSTEMS AND COMPOSITIONS FOR DIAGNOSIS OF BARRETT OSOPHAGES AND METHOD OF USE THEREOF | |
WO2015013330A3 (en) | Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof | |
MX2014014464A (es) | Peptidos penetrantes de celulas y metodos para identificar peptidos penetrantes de celulas. | |
MX2012009847A (es) | Celulasas de familia 5 modificada y usos de las mismas. | |
MX2013012791A (es) | Analogos del factor b del complemento y sus usos. | |
NZ706884A (en) | Fc gamma receptor iib variants | |
JP2010265269A5 (es) | ||
IN2014DN09367A (es) | ||
MX347541B (es) | Analogos de acido sialico. | |
EA201690966A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
GB201118201D0 (en) | Novel peptides | |
IN2014MN01376A (es) | ||
WO2013117348A8 (en) | Agonists and antagonists of toll-like receptor (tlr) 13 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |